黑料网

Drug metabolism; Therapeutic outcomes; Microorganisms; Microbial transformation; Biocatalysis synthesis; Pharmacokinetics modeling

Introduction

The study of drug metabolism is a critical aspect of pharmacology, as it influences the efficacy, safety, and pharmacokinetics of pharmaceutical agents. Understanding how drugs are metabolized in the body is essential for optimizing drug therapy and minimizing adverse effects. While traditional approaches to studying drug metabolism have relied heavily on human enzymes and animal models, the use of microorganisms has emerged as a valuable and complementary tool in this field. This introduction provides an overview of the growing role of microorganisms in the study of drug metabolism, highlighting their unique capabilities and applications. Microorganisms, including bacteria, fungi, and yeasts, possess a diverse array of metabolic enzymes that can catalyze a wide range of chemical transformations [1]. These microbial enzymes often exhibit similarities to human drug-metabolizing enzymes, allowing microorganisms to serve as simplified models for studying drug metabolism pathways. By harnessing the metabolic capabilities of microorganisms, researchers can simulate, elucidate, and predict drug metabolism reactions in a controlled laboratory setting [2].

Description

In the realm of pharmacology and drug development, understanding how drugs are metabolized in the body is crucial for optimizing their efficacy and safety profiles. While much of the focus traditionally falls on human metabolic pathways, the use of microorganisms has emerged as a valuable tool in studying drug metabolism. Microorganisms, including bacteria, fungi, and yeasts, possess metabolic capabilities that can mimic, complement, or even surpass those of human enzymes. This article explores the diverse ways in which microorganisms are employed in the study of drug metabolism and their implications for pharmaceutical research and development [3].

Microbial transformation: mimicking human metabolism

Microorganisms possess a wide array of enzymes capable of catalyzing drug metabolism reactions, including oxidation, reduction, hydrolysis, and conjugation. These enzymatic activities often parallel those found in human cells, allowing microorganisms to serve as simplified models for studying drug metabolism pathways [4]. By incubating drugs with specific microbial strains under controlled conditions, researchers can simulate metabolic transformations that occur in the human body. This approach provides valuable insights into potential metabolic pathways, metabolite identification, and the kinetics of drug metabolism reactions [5].

Biocatalytic synthesis: enzymatic conversions

Microorganisms offer a unique platform for the biocatalytic synthesis of drug metabolites and analogs. Through genetic engineering and directed evolution techniques, microbial enzymes can be engineered or optimized to catalyze specific metabolic reactions with high efficiency and selectivity [6]. This enables the production of metabolites that may be challenging to obtain through chemical synthesis or isolation from biological matrices. Biocatalytic synthesis using microorganisms not only facilitates the preparation of metabolites for pharmacological testing but also provides a sustainable and environmentally friendly approach to drug synthesis [7].

Drug screening and metabolite profiling: high-throughput approaches

Microorganisms are increasingly utilized in high-throughput screening assays to evaluate drug metabolism and identify potential drug candidates. Microbial systems offer advantages such as rapid growth rates, scalability, and genetic tractability, making them well-suited for screening large compound libraries. By exposing microorganisms to diverse chemical compounds and analyzing the resulting metabolic profiles, researchers can identify lead compounds, predict metabolic liabilities, and prioritize candidates for further development. Microbial screening assays also enable the rapid assessment of drugdrug interactions and the identification of potential metabolites with pharmacological activity [8,9].

Pharmacokinetic studies: predicting in vivo behavior

Microorganisms play a valuable role in predicting the in vivo pharmacokinetics of drugs and their metabolites. By incorporating microbial metabolism data into pharmacokinetic models, researchers can simulate drug disposition, metabolism, and elimination in various physiological compartments. This approach aids in predicting plasma concentration-time profiles, drug clearance rates, and the potential for drug-drug interactions. Microbial systems offer a cost-effective and efficient means of generating pharmacokinetic data early in the drug development process, guiding decision-making and reducing the risk of late-stage failures [10].

Conclusion

The use of microorganisms in the study of drug metabolism offers numerous advantages, ranging from their ability to mimic human metabolic pathways to their utility in biocatalytic synthesis and high-throughput screening assays. By harnessing the metabolic capabilities of microorganisms, researchers can gain valuable insights into drug metabolism, identify potential drug candidates, and optimize pharmacokinetic parameters. As pharmaceutical research continues to evolve, microorganisms are poised to play an increasingly important role in advancing our understanding of drug metabolism and facilitating the development of safe and effective therapeutics.

1. Emwas AH, Szczepski K, Poulson BG, Chandra K, McKay RT, et al. (2020) . Molecules 25: 4597.

, ,

2. Li Q, Kang CB (2020) . Molecules 25: 2974.

, ,

3. Pellecchia M, Bertini I, Cowburn D, Dalvit C, Giralt E, et al. (2008) . Nat Rev Drug Discov 7: 738-745.

, ,

4. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) . Science 274: 1531-1534.

, ,

5. Lamoree B, Hubbard RE (2017) . Essays Biochem 61: 453-464.

, ,

6. Harner MJ, Frank AO, Fesik SW (2013) . J Biomol NMR 56: 65-75.

, ,

7. Li Q (2020) . Front Mol Biosci 7: 180.

, ,

8. Murray CW, Rees DC (2009) . Nat Chem 1: 187-192.

, ,

9. Ayotte Y, Murugesan JR, Bilodeau F, Larda S, Bouchard P, et al. (2017) . Protein Sci 26: 194-195.
10. Erlanson DA, Fesik SW, Hubbard RE, Jahnke W, Jhoti H (2016) . Nat Rev Drug Discov 15: 605-619.

, ,